SCAI Stages of Cardiogenic Shock and Mortality Risk

The SCAI stages of cardiogenic shock are a five-level classification system, running from Stage A through Stage E, that categorizes patients based on how severely their heart is failing to pump enough blood. Developed by the Society for Cardiovascular Angiography and Interventions and endorsed by four major professional societies in 2019, the framework gave clinicians a shared vocabulary for a condition that had long been treated as a single entity despite enormous variation in severity.¹ The classification matters because mortality in cardiogenic shock can range from low single digits at the mildest end to nearly 90 percent at the most severe, and matching the right treatments to the right stage can change outcomes.

The Five Stages at a Glance

Each stage carries a mnemonic label that tracks the clinical picture in plain terms:

Stage A, “At Risk”: The patient has a condition that could lead to cardiogenic shock, such as a large heart attack or severe heart failure, but shows no signs of hemodynamic compromise right now. Blood pressure is normal, and there is no evidence of poor organ perfusion.
Stage B, “Beginning”: Early signs of instability are present. Blood pressure may be low or heart rate elevated, and the patient might need a low dose of a vasopressor or inotrope. The critical distinction is that there is no evidence yet that organs are being starved of blood flow.
Stage C, “Classic”: This is what most textbooks historically described when they said “cardiogenic shock.” The hallmark is hypoperfusion, meaning organs are not receiving adequate blood flow. A patient in Stage C typically has low blood pressure, elevated lactate, cool extremities, reduced urine output, or some combination of these findings.
Stage D, “Deteriorating”: The initial round of interventions, whether medications or devices, has failed to restore adequate perfusion after at least 30 minutes. The patient is getting worse despite active treatment and needs escalation.
Stage E, “Extremis”: The patient is in or near circulatory collapse, frequently experiencing refractory cardiac arrest with ongoing CPR or being supported by multiple simultaneous acute interventions, including extracorporeal membrane oxygenation.

The dividing line that matters most in this system is between Stage B and Stage C. Below that line, the patient is unstable but perfusing. Above it, organs are suffering.² That distinction drives much of the decision-making about when to escalate therapy.³

How Mortality Tracks With Stage

The classification was built by expert consensus, but multiple validation studies have since confirmed that higher stages correspond to progressively worse survival. In a study of acute myocardial infarction patients from the National Cardiogenic Shock Initiative, about 76 percent of patients presenting in Stage C or Stage D survived to hospital discharge, compared to 58 percent of those presenting in Stage E.⁴ Among patients who were still in Stage E at 24 hours, survival dropped below 20 percent regardless of what stage they had started in.

A separate analysis of over 3,400 patients, in whom shock was caused by heart failure in about half and by heart attack in roughly a third, used objective lab values to define thresholds for each stage. Systolic blood pressure, lactate level, alanine transaminase (a marker of liver injury), and blood pH were the variables most strongly tied to mortality and were used to anchor each stage’s criteria.⁵ Overall mortality in that cohort was 35 percent, with higher death rates among patients who had experienced out-of-hospital cardiac arrest or who required increasing numbers of drugs and devices.

A study from a middle-income country applied the SCAI system on admission and found 30-day mortality rates that climbed steeply: roughly 6 percent for Stage A, 8 percent for Stage B, 62 percent for Stage C, 75 percent for Stage D, and 88 percent for Stage E.⁶ After adjusting for other risk factors, each step up in SCAI stage remained independently associated with higher mortality. The consistency of these findings across different populations and causes of shock is one reason the classification has gained traction quickly.

Why a Single Snapshot Is Not Enough

One of the most important developments since the original 2019 publication is the recognition that cardiogenic shock is not a static condition. A patient classified as Stage B on arrival can deteriorate to Stage D or E within hours, and someone who presents in Stage C can improve to Stage B with the right treatment. Multiple studies have shown that tracking how the stage changes over time gives a more accurate picture of who will survive than any single measurement at admission.

In a large cohort of cardiac intensive care unit patients, serial reassessment every four hours substantially improved mortality prediction compared to the admission stage alone. The mean SCAI stage over the ICU stay had the highest discriminative ability, and each additional four-hour block that a patient met criteria for shock independently predicted higher mortality.⁷ A separate critical-care study found similar results, with the mean stage outperforming both the admission stage and the maximum stage reached.⁸ That study also found that nearly a third of patients developed late-onset shock after initially appearing stable, reinforcing the need for repeated checks.

Another retrospective cohort study confirmed this pattern, finding that the highest SCAI stage reached during the ICU stay and the overall trajectory of shock evolution both outperformed the admission stage alone in predicting outcomes.⁹ In practical terms, this means that classifying a patient once at the door and moving on is not good enough. Teams that reassess stage regularly can catch deterioration earlier and escalate treatment before the patient crosses into a stage where interventions become much less effective.

A study of acute myocardial infarction patients made this point starkly: among those who started at Stage B or higher and worsened within 24 hours, 30-day mortality was roughly 93 percent, whereas those who entered at Stage C or above but stayed stable or improved had a 30 percent mortality rate.¹⁰ Direction of travel matters at least as much as the stage on arrival.

The Role of Cardiac Arrest as a Risk Modifier

The original SCAI framework was designed to classify hemodynamic severity, but certain clinical events add risk on top of whatever stage a patient occupies. Cardiac arrest is the most studied of these modifiers. In a cardiac intensive care unit cohort, patients who had experienced cardiac arrest had a hospital mortality of 34 percent compared to 6 percent among those without arrest. After adjusting for other variables, cardiac arrest tripled the odds of dying. Patients whose arrest rhythm was not ventricular fibrillation fared even worse, with a mortality of 44 percent versus 25 percent for those with ventricular fibrillation arrest.¹¹ The increased risk held across nearly every SCAI stage, except Stage E, where mortality was already so high that the additional effect of arrest was washed out.

More recent work has pushed back on treating cardiac arrest as a simple yes-or-no modifier. A study of infarction-related cardiogenic shock with out-of-hospital cardiac arrest found that outcomes varied depending on the circumstances of the arrest. Favorable arrest characteristics were associated with a lower adjusted risk of 30-day death, while unfavorable characteristics raised it, compared to patients with infarction-related shock who had no cardiac arrest at all.¹² The implication is that simply checking a box for “cardiac arrest present” misses the nuance. Not all arrests carry the same prognosis, and future iterations of the classification may need to characterize the arrest more carefully rather than using it as a binary flag.

Guiding Mechanical Circulatory Support Decisions

One of the most consequential applications of the SCAI stages is helping teams decide when and whether to deploy mechanical circulatory support devices, such as percutaneous ventricular assist devices or extracorporeal membrane oxygenation. The staging system gives a shared framework for these high-stakes, time-sensitive decisions.

Current expert guidance suggests that temporary mechanical circulatory support should be strongly considered in Stage C and Stage D patients when hypoperfusion persists despite initial medical therapy, and ideally before procedures like coronary intervention when feasible. In Stage E, however, where multi-organ failure is often already established, the benefit of mechanical support drops considerably and must be weighed on a case-by-case basis.¹³ This is a critical nuance: there is a window in which device support can change the trajectory, and the SCAI stages help identify that window. Wait too long and the patient may be beyond the point where mechanical support meaningfully helps.

An analysis of patients receiving short-term mechanical circulatory support for various indications confirmed that the SCAI stage distribution varies by clinical scenario. Patients undergoing planned complex high-risk coronary intervention tended to be at less advanced stages, while those with postcardiotomy shock, myocarditis, pulmonary embolism, refractory cardiac arrest, or electrical storm presented at more advanced stages.¹⁴ The staging system seems to function well across these varied contexts, though some conditions may warrant additional clinical judgment beyond the stage alone.

The Value of Hemodynamic Monitoring

Invasive hemodynamic assessment using a pulmonary artery catheter has been somewhat controversial in critical care over the past two decades, but in cardiogenic shock specifically, it appears to matter. A study examining patients who received mechanical circulatory support found that completing a full pulmonary artery catheter assessment before device placement was associated with the lowest in-hospital mortality, compared to patients who had an incomplete assessment or none at all. This mortality benefit held across each SCAI stage subgroup.¹⁵

Knowing the actual filling pressures, cardiac output, and vascular resistance helps clinicians assign the correct SCAI stage with more confidence and select the right type of support. A patient who looks like Stage C on the basis of a low blood pressure and elevated lactate might turn out to have a different hemodynamic profile than expected, changing the treatment approach entirely. The SCAI framework identifies the severity, and hemodynamic data helps explain the mechanism behind it.

Protocol-Driven Care and Speed of Intervention

Having a classification system is only useful if teams act on it in a coordinated, timely way. A study of Asian patients treated under an evolving protocol-driven approach to cardiogenic shock found that survival improved as centers achieved more best-practice benchmarks. Patients in whom all three defined best practices were met had a 30-day survival rate of 75 percent, compared to roughly 36 percent in those where one or fewer were achieved. Over time, the proportion of patients receiving all best practices rose, and the median time from shock recognition to device placement dropped from 5 hours to 1.5 hours. In multivariate analysis, a delay of more than 180 minutes from shock to device placement independently predicted death.¹⁶

These findings reinforce a broader theme in cardiogenic shock management: time is tissue, and the SCAI stages serve as a common language that can speed up the decision chain. When a nurse, an interventional cardiologist, a heart failure specialist, and a cardiac surgeon all understand that a patient is Stage D and deteriorating, the conversation about escalation starts faster. Without that shared framework, teams often describe the same patient differently depending on their subspecialty, losing time in translation.

Organ Damage Beyond the Heart

Cardiogenic shock does not damage just the heart. When the heart cannot pump enough blood, every organ downstream is at risk, and the kidneys are often among the first to show injury. A study stratifying acute kidney injury by SCAI shock stage found that worsening kidney injury was independently associated with higher hospital mortality overall. In patients at SCAI Stage A or B, the degree of kidney injury significantly predicted death. In patients already at Stage C, D, or E, however, adding kidney injury staging did not meaningfully improve mortality prediction, likely because the severity of shock itself was already the dominant driver of outcomes at those stages.¹⁷

This finding has practical implications. For patients at the lower end of the shock spectrum, clinicians should watch kidney function closely as an early warning sign of worsening perfusion that might not yet be reflected in the SCAI stage. For patients already deep into shock, the focus shifts to restoring cardiac output as the single most impactful intervention.

Challenges in the Prehospital Setting

One major limitation of the SCAI classification is that it relies on data that may not be available until the patient reaches a hospital. Cardiogenic shock presents in varied ways, and many of the clinical and laboratory markers used to assign a stage, such as lactate levels, liver enzymes, and hemodynamic measurements, are not accessible to paramedics in the field. Prehospital providers often have to rely on vital signs, clinical appearance, and electrocardiogram findings, which can overlap with other types of shock and make cardiogenic shock difficult to distinguish early.¹⁸

This gap matters because, as the evidence on trajectory shows, early recognition and rapid escalation improve outcomes. If the first opportunity to assign a SCAI stage is after arrival at a cardiac catheterization lab, precious time has already been lost. Efforts to develop simplified prehospital screening tools that can flag patients likely to be in Stage C or higher are ongoing, but the field is not there yet. For now, the staging system is most powerful once the patient is inside a facility with access to labs and monitoring.

Applicability Across Different Settings and Causes

The SCAI stages were originally conceived with acute myocardial infarction in mind, but subsequent work has validated the system across other causes of cardiogenic shock. An analysis of over 2,400 patients found that heart failure accounted for about 55 percent of cases and myocardial infarction for about 26 percent. Increasing SCAI stage at baseline and the maximum stage reached were both significantly associated with in-hospital mortality regardless of the underlying cause.¹⁹ A separate study demonstrated that the graded relationship between shock severity and mortality held even after stratifying patients by diagnosis, treatment type, and underlying cause.²⁰

The system has also been tested in resource-limited settings. In a tertiary care center in a middle-income country, the same stepwise increase in mortality across SCAI stages was observed, with adjusted hazard ratios climbing from about 1.4 for Stage C to 3.4 for Stage E, using Stage A as the reference.²¹ This suggests the classification captures something fundamental about shock physiology that transcends differences in available technology and treatment patterns.

Lactate Clearance as a Potential Complement

One area of active development is integrating lactate clearance, the speed at which elevated blood lactate levels fall after treatment begins, into the SCAI framework. Lactate is already one of the markers used to identify hypoperfusion and assign a stage, but the rate at which it normalizes may carry independent prognostic information. The SCAI has launched a “Door to Lactate Clearance” initiative exploring whether this metric can be standardized as a treatment target, somewhat analogous to the “door to balloon” time metric that transformed heart attack care. The idea is that a patient who starts at Stage C but whose lactate drops rapidly after intervention is on a fundamentally different trajectory than one whose lactate remains stubbornly elevated, even if both begin at the same stage. Formal validation studies are still needed, but the concept reflects the broader shift toward dynamic, real-time assessment rather than one-time classification.

The evolution of the SCAI stages from a static expert consensus in 2019 to a dynamic, trajectory-aware, and increasingly data-driven tool represents one of the faster translations from classification to clinical workflow in cardiovascular medicine. The stages do not tell clinicians what to do for any individual patient, but they give every member of a shock team a shared, graded understanding of how sick the patient is right now, how sick the patient was an hour ago, and where things appear to be headed. That shared understanding, more than any specific cutoff or threshold, is what makes the system useful at the bedside.